ArticleNeuro-oncology advances
miRNA liquid biopsy combined with MRI radiomics for improved outcome prediction in glioblastoma: integrated machine learning analysis of longitudinal data from 73 patients.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Radiogenomics and CSF-Based Liquid Biopsy Sequencing for Precision Neuro-Oncology.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While both MRI radiomics and miRNA liquid biopsy have shown promise for glioblastoma prognostication, state-of-the-art methods may enable novel integration of multimodal data to further optimize performance. Methods: Serum samples ( Results: The recurrence rate was 75% (median 222 days, IQR [93-378]), and post-recurrence mortality was 62% (412 days, [274-695]) during the follow-up period. Radiomics outperformed miRNAs for recurrence prediction (time-averaged AUC = 0.66 [0.60-0.71] versus AUC = 0.56 [0.53-0.59]), while miRNAs outperformed radiomics for survival prediction (AUC = 0.70 [0.64-0.77] versus AUC = 0.55 [0.47-0.60]). Combined miRNA+radiomics models performed well for recurrence (AUC = 0.64 [0.44-0.80]) and best overall for survival (AUC = 0.76 [0.63-0.86]). Several performance-driving miRNAs were also identified on CA and SHAP analyses. Conclusions: Serum miRNA profiling combined with MRI radiomics may improve longitudinal approximation of postoperative glioblastoma prognosis. Integrating multimodal data is feasible and could enable more informed counseling of patients and families over the disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.